Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,259B 71.26B 63.72B 58.37B 53.19B 99.64B 6,763B 102B 692B 281B 3,566B 267B 262B P/E 2026 *
22.1x
P/E 2027 * 19.5x
Enterprise Value 10,234B 64.77B 57.92B 53.05B 48.34B 90.57B 6,148B 92.63B 629B 255B 3,241B 243B 238B EV / Sales 2026 *
7.35x
EV / Sales 2027 * 6.63x
Free-Float
38.12%
Yield 2026 *
1.97%
Yield 2027 * 2.23%
1 day+0.31%
1 week+0.71%
Current month+0.31%
1 month+10.82%
3 months-1.28%
6 months-17.00%
Current year-16.98%
1 week 6,522
Extreme 6522
6,922
1 month 5,979
Extreme 5979
6,922
Current year 5,974
Extreme 5974
10,700
1 year 5,974
Extreme 5974
10,700
3 years 4,572
Extreme 4572
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.333333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 28/02/2021
Director of Finance/CFO 59 27/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 29/02/2020
Director/Board Member 59 27/03/2024
Director/Board Member 51 28/02/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%+0.71%-2.92%+47.92% 71.26B
-0.46%+10.80%+63.52%+154.48% 1,263B
-0.97%+2.56%+43.25%+81.96% 658B
-2.05%+1.12%+32.47%+102.74% 521B
-1.54%+1.61%+53.42%+67.10% 391B
-0.78%+2.13%+72.55%+44.25% 369B
-1.69%+2.75%+32.49%+54.35% 307B
-0.72%+8.08%+11.15%+34.09% 290B
-0.12%+5.96%+55.97%+78.44% 252B
-0.21%+9.16%+42.19%+112.41% 212B
Average -0.57%+5.35%+40.41%+77.77% 433.32B
Weighted average by Cap. -0.63%+6.50%+48.29%+96.60%

Financials

2026 *2027 *
Net sales 1,393B 8.81B 7.88B 7.22B 6.58B 12.33B 837B 12.61B 85.6B 34.75B 441B 33.09B 32.39B 1,522B 9.63B 8.61B 7.89B 7.19B 13.47B 914B 13.78B 93.54B 37.97B 482B 36.16B 35.4B
Net income 510B 3.23B 2.88B 2.64B 2.41B 4.51B 306B 4.61B 31.32B 12.71B 161B 12.11B 11.85B 577B 3.65B 3.26B 2.99B 2.72B 5.1B 347B 5.22B 35.45B 14.39B 183B 13.7B 13.42B
Net Debt -1,025B -6.49B -5.8B -5.31B -4.84B -9.07B -616B -9.28B -62.99B -25.57B -325B -24.35B -23.84B -1,165B -7.37B -6.59B -6.04B -5.5B -10.31B -700B -10.54B -71.58B -29.06B -369B -27.67B -27.09B
Projected Income Statement - Annual - Chugai Pharmaceutical Co., Ltd.
Logo Chugai Pharmaceutical Co., Ltd.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Employees
5,104
Date Price Change Volume
02/11/26 JP¥6,843.00 +0.31% 3,195,800
30/10/26 JP¥6,822.00 +2.54% 3,076,400
29/10/26 JP¥6,653.00 +0.59% 4,547,300
28/10/26 JP¥6,614.00 -1.11% 3,542,700
27/10/26 JP¥6,688.00 -3.03% 3,220,000
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Chugai Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,843.00JPY
Average target price
8,446.67JPY
Spread / Average Target
+23.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Chugai Pharmaceutical Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4519 Stock